share_log

復星醫藥：聯合公告(1)以吸收合併復宏漢霖之方式由復星新藥對復宏漢霖附前提條件私有化之建議(2)建議撤銷上市(3)復星醫藥之可能須予披露交易及(4)恢復買賣

FOSUN PHARMA: JOINT ANNOUNCEMENT (1) PROPOSED PRE-CONDITIONAL PRIVATISATION OF HENLIUS BY FOSUN NEW MEDICINE BY WAY OF MERGER BY ABSORPTION OF HENLIUS (2) PROPOSED WITHDRAWAL OF LISTING (3) POSSIBLE DISCLOSEABLE TRANSACTION OF FOSUN PHARMA AND (4) RESUMPTION OF TRADING

Hong Kong Stock Exchange ·  Jun 24 22:28
Summary by Futu AI
上海復星醫藥（集團）股份有限公司（復星醫藥）宣佈，於2024年6月24日與上海復星新藥研究有限公司（復星新藥）簽訂合併協議，據此復星新藥將吸收合併復宏漢霖，並提出私有化建議。合併完成後，復宏漢霖將註銷在中國的登記，並撤銷在香港聯合交易所有限公司（聯交所）的上市地位。合併協議包含支付每股H股24.60港元及每股非上市股份人民幣22.444794元的註銷價。此外，復星醫藥保留在合併完成前允許新投資者認購或收購復星新藥股份的權利。合併預計將以內部現金資源及/或外部債務融資支付，包括由復星新藥與招商銀行股份有限公司上海分行訂立的貸款融資。合併的實施條件包括獲得相關政府部門的批准、股東大會的通過及其他法律程序的完成。H股已於2024年5月23日暫停買賣，並於2024年6月25日恢復買賣。合併協議的生效與否尚存在不確定性，股東及潛在投資者應謹慎行事。
上海復星醫藥（集團）股份有限公司（復星醫藥）宣佈，於2024年6月24日與上海復星新藥研究有限公司（復星新藥）簽訂合併協議，據此復星新藥將吸收合併復宏漢霖，並提出私有化建議。合併完成後，復宏漢霖將註銷在中國的登記，並撤銷在香港聯合交易所有限公司（聯交所）的上市地位。合併協議包含支付每股H股24.60港元及每股非上市股份人民幣22.444794元的註銷價。此外，復星醫藥保留在合併完成前允許新投資者認購或收購復星新藥股份的權利。合併預計將以內部現金資源及/或外部債務融資支付，包括由復星新藥與招商銀行股份有限公司上海分行訂立的貸款融資。合併的實施條件包括獲得相關政府部門的批准、股東大會的通過及其他法律程序的完成。H股已於2024年5月23日暫停買賣，並於2024年6月25日恢復買賣。合併協議的生效與否尚存在不確定性，股東及潛在投資者應謹慎行事。
Fosun Pharma (Shanghai Fosun Pharmaceutical (Group) Co., Ltd.) announced that it has signed a merger agreement with Shanghai Fosun New Medical Research Co., Ltd. (Fosun New Medical) on June 24, 2024. According to the agreement, Fosun New Medical will absorb and merge with Henlius and proposes a privatization plan. After the merger is completed, Henlius will be deregistered in China and the listed status on the Stock Exchange of Hong Kong Limited (SEHK) will be canceled. The merger agreement includes a cancellation price of HKD 24.60 per H share and CNY 22.444794 per non-listed share. In addition, Fosun Pharma reserves the right to allow new investors to subscribe to or acquire shares of Fosun New Medical before the completion of the merger. The...Show More
Fosun Pharma (Shanghai Fosun Pharmaceutical (Group) Co., Ltd.) announced that it has signed a merger agreement with Shanghai Fosun New Medical Research Co., Ltd. (Fosun New Medical) on June 24, 2024. According to the agreement, Fosun New Medical will absorb and merge with Henlius and proposes a privatization plan. After the merger is completed, Henlius will be deregistered in China and the listed status on the Stock Exchange of Hong Kong Limited (SEHK) will be canceled. The merger agreement includes a cancellation price of HKD 24.60 per H share and CNY 22.444794 per non-listed share. In addition, Fosun Pharma reserves the right to allow new investors to subscribe to or acquire shares of Fosun New Medical before the completion of the merger. The merger is expected to be paid by internal cash resources and/or external debt financing, including loan financing from Fosun New Medical and the Shanghai Branch of China Merchants Bank Co., Ltd. The implementation conditions of the merger include obtaining approval from relevant government departments, approval from shareholders' meetings, and completion of other legal procedures. H shares were suspended from trading on May 23, 2024, and resumed trading on June 25, 2024. The effectiveness of the merger agreement is uncertain, and shareholders and potential investors should proceed with caution.

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.